Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.

Line Brøndum Brita Singers SørensenChristian MaareJørgen JohansenHanne PrimdahlJan Folkvard EvensenClaus Andrup KristensenLisbeth Juhler AndersenJens OvergaardJesper Grau Eriksen

Published in: Acta oncologica (Stockholm, Sweden) (2018)

Moderate to severe skin rash after zalutumumab during radiation treatment was associated with improved OS, independent of HPV/p16-status. Genetic variants in AREG (member of the EGF family) may be associated with increased risk of skin rash.

Keyphrases

soft tissue
wound healing
small cell lung cancer
clinical trial
high grade
epidermal growth factor receptor
study protocol
randomized controlled trial
tyrosine kinase
phase ii
radiation induced
drug induced